StemMACS™ HSC-CFU Media, human

StemMACS™ HSC-CFU Media, human

StemMACS HSC-CFU Media have been developed for the expansion of CD34
+
cells and to assess the differentiation potential of human hematopoietic stem and progenitor cells as Colony Forming Units (CFU). They are ideally suited for use with
  • unseparated blood3 , bone marrow4 , or fetal liver cells
  • sorted cell populations1,4
  • or ES and iPS cell-derived hematopoietic precursors2
StemMACS HSC-CFU Media are standardized semi-solid media based on methylcellulose in IMDM, supplemented with FBS, BSA, and different growth factors. StemMACS HSC-CFU media are designed to maximize growth and differentiation of progenitor cells and allow the clonal progeny of a single cell to grow in a distinct cluster or colony. They are produced under tightly controlled manufacturing conditions and use highly qualified raw materials to provide a consistent and optimally performing colony assay.
StemMACS HSC-CFU media are available in different formats.

Technical data

Formulation of StemMACS HSC-CFU media

Technical data

Formulation of StemMACS HSC-CFU media
  • Selected references

    1. Lambert et al. (2009)
      In essential thrombocythemia, multiple
      JAK2
      -V617F clones are present in most mutant-positive patients: a new disease paradigm.
      Blood 114: 3018-3023
    2. Tormin et al. (2011)
      CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with
      in situ
      localization.
      Blood 117: 5067-5077
    3. Zhou et al. (2011) The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118: 2830-2839
    4. Bissels et al. (2011)
      Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133
      +
      and CD34
      +
      hematopoietic stem and progenitor cells.
      Stem Cells 29: 847-857
    5. Liu, G.H. et al. (2014) Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs. Nat Commun 5: 4330
    6. Brault, J. et al. (2014)
      Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells:
      ex vivo
      models of X
      0
      -linked, AR22
      0
      - and AR47
      0
      - chronic granulomatous diseases.
      Biores Open Access 3(6): 311-326
    7. Venton, G. et al. (2016) Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. Blood Cancer J. 6(9): 469
    8. Del Fante, C. et al. (2005)
      Immunomagnetic cell selection performed for HLA haploidentical transplants with the CliniMACS device: effect of additional platelet removal on CD34
      +
      cell recovery.
      Stem Cells Dev. 14: 734-739
    9. Chang et al. (2006) Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin Blood 108: 1515-1523
    10. Biedermann, B. et al. (2007) Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors. Leuk. Res. 31: 211-220
    11. Watts et al. (2008) Cytotherapy 10(suppl. 1): poster no. 150
  • Brochures and posters

  • Scientific posters

Product options: 4
100 mL
EUR 456,00 
100 mL
EUR 391,00 
100 mL
EUR 396,00 
80 mL
EUR 181,00 

Related products

4 products available